Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10719MR)

This product GTTS-WQ10719MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10719MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14321MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG7414
GTTS-WQ12970MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ8151MR IVTScrip™ mRNA-Anti-TNFRSF1A, HL036337(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HL036337
GTTS-WQ15334MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ3057MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ14478MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RO-7105705
GTTS-WQ11794MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ10176MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LC1004-002
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW